


Provided for non-commercial research and education use.

Not for reproduction, distribution or commercial use.



Egyptian Academic Journal of Biological Sciences is the official English language journal of the Egyptian Society for Biological Sciences, Department of Entomology, Faculty of Sciences Ain Shams University.

Physiology & molecular biology journal is one of the series issued twice by the Egyptian Academic Journal of Biological Sciences, and is devoted to publication of original papers that elucidate important biological, chemical, or physical mechanisms of broad physiological significance.

www.eajbs.eg.net



Determination OF Apolipoprotein (E) Genotypes By PCR And Relation To Plasma Lipid In Coronary Heart Disease Patients

Hassan, S. E. I.¹ ; Naglaa Kholoussi¹ and Randa, M. Taalat²

1- Immunogenetics Dept National Research Center

2- Molecular Diagnostic Dept Institute of Genetics Engineering and Biotechnology
Menoufia University

ARTICLE INFO

Article History

Received: 1/3/2016

Accepted: 20/4/2016

Keywords:

Apolipoprotein E,
Coronary artery
disease,

ABSTRACT

Coronary artery disease (CAD) is the most prevalent type of cardiovascular disease (CVD) which, according to the American Heart Association accounts for 35% of all deaths in U.S.A. Apolipoprotein E (ApoE) is an apoprotein found in the chylomicrons and IDLs that binds to a specific receptor on liver cells and peripheral cells and it is essential for the normal catabolism of triglyceride-rich lipoprotein constituents. This study was carried out on 35 subjects divided into two groups. First : 25 CAD patients, the patients ages were ranged between 43 to 71 years. Second : 10 control were normal, the control ages were ranged between 29-54 years. All the patients and control were selected from Cairo Medical Center, cardiology department.

All subjects were submitted to the following:

1. Full history taking.
2. General clinical examination.
3. Coronary angiography (transfemoral catheterization).
4. Laboratory investigation:
 - Assessment of apolipoprotein E polymorphism by PCR and restriction enzymes.
 - Measurement of serum cholesterol.
 - Measurement of serum triacylglycerol.
 - Measurement of serum low density lipoprotein cholesterol (LDLc).
 - Measurement of serum high density lipoprotein cholesterol (HDLc).
 - Measurement of serum cardiac enzymes and troponine.

INTRODUCTION

Coronary artery disease (CAD) also called coronary heart disease (CHD) is defined as a condition in which a plaque builds up inside the coronary arteries and this plaque narrows the arteries and reduces blood flow to the heart muscle (NHLPI, 2009).

Coronary artery disease (CAD) is the most prevalent type of cardiovascular disease (CVD) which, according to the American Heart Association accounts for 35% of all deaths in U.S.A (Corwin, 2008).

Apolipoprotein E (ApoE) is an apoprotein found in the chylomicrons and IDLs that binds to a specific receptor on liver cells and peripheral cells and it is essential for the normal catabolism of triglyceride-rich lipoprotein constituents (Entrez Gene, 2009).

The ApoE gene (ApoE) is mapped to chromosome 19 in a cluster with apolipoprotein C1 and apolipoprotein C2, ApoE consists of four exons and three introns, totaling 3597 base pairs (Hoek *et al.*, 2008).

The genetic polymorphism of ApoE results from the existence of three common co-dominant alleles (E2, E3, and E4) that code for three apolipoprotein isoforms (E2, E3, and E4) resulting in six common genotypes (E2E2, E2E3, E2E4, E3E3, E3E4, and E4E4) (Tascilar *et al.*, 2009).

These isoforms differ from each other only by single amino acid substitution at position 112 and 158, but have profound physiological consequences (Entrez Gene, 2009).

The most frequent isoform E3 contains a cysteine at residue 112 and an arginine at residue 158. E2 and E4 differ from the E3 isoform in the fact that the E2 isoform contains a cysteine at residue 158 and the E4 contains an arginine at residue 112 (Chaaba *et al.*, 2008).

Plasma lipids are ApoE isoform dependent and it has been reported in association with atherosclerotic vascular disease (Graner *et al.*, 2008; Tascilar *et al.*, 2009).

Lipoproteins play a central role in development of atherosclerotic vascular disease, so, with their ability to affect lipid level, the ApoE polymorphism could be one of the factors influencing

development of atherosclerosis (Chaaba *et al.*, 2008).

The ApoE gene is one of the candidate genes for the risk of CHD, the E4 allele of the ApoE gene is maladaptive in the developed world leading to increased risk of CHD, consequently, the derived E3 allele is adaptive in the modern environment (Ding and Kullo, 2009).

The ApoE4 allele was found to be associated with high LDLc and CAD in type 2 diabetes (Chaaba *et al.*, 2008).

AIM OF THE WORK

The aim of this work is to determine the relation between apolipoprotein E polymorphism with the lipid profile in atherosclerotic coronary artery diseases.

SUBJECTS and METHODS

Subjects:

This study was carried out on 35 subjects: 25 coronary artery disease patients (8 females and 17 males) who angiographically had stenosis in at least one of the major coronary vessels and 10 subjects as control group consisted of (6 females and 4 males) who underwent angiography procedures and were normal. All The patients and control were selected from Cairo Medical Center, Cardiology Department, The patient's ages were ranged between 43 to 71 years. The controls ages were ranged between 29 to 54 years. The excluding criteria for enrollment into the study included familial hypercholesterolemia, cancer, renal disease, and any other chronic illnesses. The genotypes were grouped in three groups: E2 group (E2E2, E2E3), E3 group (E3E3) and E4 group (E2E4, E3E4, E4E4) (Table 1).

Table 1: Subjects included 25 patients and 10 matched apparently healthy controls:

| No. of patients | E2E2 | E2E3 | E2E4 | E3E3 | E3E4 | E4E4 |
|-----------------|------|------|------|------|------|------|
| 25 | 1 | 17 | - | 2 | 5 | - |
| No. of controls | E2E2 | E2E3 | E2E4 | E3E3 | E3E4 | E4E4 |
| 10 | - | 6 | - | 2 | 2 | - |

Methods:

All subjects were submitted to the following:

5. Full history taking.
6. General clinical examination.
7. Coronary angiography (transfemoral catheterization).
8. Laboratory investigation:
 - Assessment of apolipoprotein E polymorphism by PCR and restriction enzymes.
 - Measurement of serum cholesterol.
 - Measurement of serum triacylglycerol.
 - Measurement of serum low density lipoprotein cholesterol (LDLc).
 - Measurement of serum high density lipoprotein cholesterol (HDLc).

Blood sampling:

10 ml of venous blood were withdrawn from the cubital vein of every subject (the patients are fasting for 12 hours). 5ml was transferred slowly into vacuated EDTA tube for isolation of White Blood Cells. The remaining 5ml was transferred slowly into a plain tube for determination of serum lipid profile.

Detection of Apolipoprotein (E)**Genotypes by PCR:****Materials used for Molecular studies:***Reagents used for DNA Extraction:*

2X Sucrose triton (PH=7.6)
 Nuclei Lysis buffer (NaCl + Na₂ EDTA) pH=8.2
 20% SDS (Sodium dodecyle Sulfate)
 20% Proteinase K Solution
 Saturated NaCl
 Absolute ethanol (95%)
 70% ethanol
 Double distilled water.

Apparatus used for Molecular studies:

Cooling centrifuge
 Thermocycler (Biometra, Germany).
 Gel electrophoresis apparatus
 MD25K UV transilluminator

Reagents used for PCR and RFLP:

Primers for Apo E gene (Eurofins MWG GmbH, Germany):

Forward: 5'-
 TCCAAGGAGCTGCAGGCGGCGCA
 Reverse: 5'-
 GCCCCGGCCTGGTACTACTGCCA

In order to yield a 218-bp DNA fragment to be detected on a 2% Agarose gel.

DreamTaq™ DNA polymerase (5U/μl) (Thermo Fisher Scientific Co., USA)

10x DreamTaq™ buffer (Thermo Fisher Scientific Co., USA)

Q-Solution, 5X (Qiagen, Germany)

dNTP mix (dATP, dCTP, dGTP and dTTP, 2 mM each)

Nuclease free water for reconstitution of lyophilized primers and preparation of working primer solutions and dNTPs solution. Restriction Enzymes: *AfIII* and *Hae II* (2,000 units (20,000U/mL) (New England BioLabs, info@neb.com, www.neb.com)

Agarose,

Ethidium bromide (10 mg/ml),

Loading dye

DNA ladder (50bp and 100bp)

Determination of CAD severity**1. Cardiac enzymes:**

- The patients with high range CK, CKMB, LDH.
- Cardiac enzymes are performed on chemistry instrument, (Beckman COULTER AU480).

2. Troponine test :

- The patients with high troponine I.
- Troponine I is measured by hormonal instruments (ARCHITECT PLUS ARC 1000).

3. Coronary Angiography and Cardiac Catheterization

Coronary angiography was the first available in vivo assessment of the coronary arteries. In this technique, an iodinated contrast agent is injected through a catheter placed at the ostium of the coronaries. The contrast agent is then visualized through radiographic

fluoroscopic examination of the heart (Chou, 2015).

RESULTS

Coronary artery disease (CAD) is the leading cause of death and premature disability. It is a complex disorder resulting from many risk factors and individuals with genetic predisposition to atherosclerosis have substantial risk for developing CAD, especially at early ages. While it is difficult to explore the relation between local vessel wall function and CAD severity, measuring DNA variants such as ApoE polymorphisms may provide a way to assess this link because of its known

effect on endothelial cell proliferation (Demet *et al.*, 2010).

As shown in Table 2, statistically significant difference between groups as regard age was recorded, while gender had non-significant effect.

Table (3) shows statistically significant difference between groups as regard DM, the rest have insignificant.

A statistically significant difference between groups as regard lipid profile, using t-test was noticed (Table 4).

Table (5) shows statistically significant difference between patients and control as regard ApoE genotyping, using Chi-square test, with p-value >0.05 NS.

Table 2: Sociodemographic criteria of CAD patients and control groups.

| Demographic Data | CAD patients | | Control | | t-test | p-value |
|--------------------|--------------|-------|---------|-------|----------------|---------|
| | (N=25) | | (N=10) | | | |
| Age (years) | | | | | | |
| Range | 43 | 71 | 29 | 54 | 52.266 | <0.001 |
| Mean±SD | 55.8 | 7.2 | 41.4 | 8.3 | | |
| | No. | % | No. | % | x ² | p-value |
| Gender | | | | | | |
| Male | 17 | 68.0% | 4 | 40.0% | 1.312 | 0.215 |
| Female | 8 | 32.0% | 6 | 60.0% | | |

Table 3: Clinical parameters in CAD patients and control groups.

| | CAD patients | | Control | | x ² | p-value |
|---------------------|--------------|-------|---------|--------|----------------|---------|
| | (N=25) | | (N=10) | | | |
| Smoking | | | | | | |
| Positive | 10 | 40.0% | 2 | 20.0% | 0.536 | 0.464 |
| Negative | 15 | 60.0% | 8 | 80.0% | | |
| Hypertension | | | | | | |
| Positive | 20 | 80.0% | 5 | 50.0% | 1.851 | 0.174 |
| Negative | 5 | 20.0% | 5 | 50.0% | | |
| DM | | | | | | |
| Positive | 14 | 56.0% | 0 | 0.0% | 7.146 | 0.007 |
| Negative | 11 | 44.0% | 10 | 100.0% | | |

Table 4: Statistical comparison between CAD patients and control groups as regards to lipid profile.

| | CAD patients | | Control | | t-test | p-value |
|------------------------------|--------------|--------|---------|-------|--------|---------|
| | (N=25) | | (N=10) | | | |
| Total cholesterol (TC) mg/dl | 258.08 | 110.74 | 165.60 | 18.85 | 3.698 | <0.001 |
| Triglyceride (TG) mg/dl | 219.56 | 108.97 | 104.70 | 23.70 | 4.651 | <0.001 |
| HDLc (mg/dl) | 50.38 | 15.89 | 46.69 | 6.71 | 2.000 | 0.032 |
| LDLc (mg/dl) | 163.79 | 106.70 | 97.97 | 19.52 | 2.729 | 0.008 |

Table 5: ApoE genotypes and alleles among CAD patients and control groups.

| | CAD patients | | Control | | x ² | p-value |
|------------------------|---------------|-------|---------------|-------|----------------|---------|
| | (N=25) | | (N=10) | | | |
| ApoE genotyping | | | | | | |
| E3/E3 | 2 | 8.0% | 2 | 20.0% | 0.176 | 0.674 |
| E2/E3 | 17 | 68.0% | 6 | 60.0% | 0.003 | 0.955 |
| E3/E4 | 5 | 20.0% | 2 | 20.0% | 0.219 | 0.640 |
| E4/E4 | 0 | 0.0% | 0 | 0.0% | 0.000 | 1.000 |
| E2/E4 | 0 | 0.0% | 0 | 0.0% | 0.000 | 1.000 |
| E2/E2 | 1 | 4.0% | 0 | 0.0% | 0.232 | 0.630 |
| ApoE genotyping | (N=50) | | (N=20) | | | |
| E2 | 19 | 38.0% | 6 | 30.0% | 0.126 | 0.723 |
| E3 | 26 | 52.0% | 12 | 60.0% | 0.117 | 0.723 |
| E4 | 5 | 10.0% | 2 | 10.0% | 0.194 | 0.659 |

DISCUSSION

Coronary arteries supply blood to the heart muscle. Like all other tissues in the body, the heart muscle needs oxygen-rich blood to function, and oxygen-depleted blood must be carried away. The coronary arteries run along the outside of the heart and have small branches that dive into the heart muscle to bring it blood (Mazur *et al.*, 2015).

Apolipoprotein E is a plasma glycoprotein and a member of the apo gene family, it is located at chromosome 19q13.2, and consists of four exons and three introns spanning 3.597 nucleotides, and produces a 299 amino acid polypeptide with a molecular mass of about 34 kDa (Demet *et al.*, 2010).

Apolipoprotein E has a storied history as a lipid transport protein (Hauser *et al.*, 2010). Apo E is a constituent of triglyceride-rich lipoproteins and high density lipoproteins. Its major function is to mediate the binding of lipoprotein particles to cell surface receptors (Grammer *et al.*, 2011).

Apo E serves as a ligand for the apo B, E receptor, and the LDL receptor related protein and thus it plays a prominent role in the transportation and redistribution in both the influx and efflux of cholesterol in the body (Fallah *et al.*, 2011)

The receptor binding properties of ApoE are strongly influenced by isoform

specific amino acid differences as well as the lipidation state of the protein (Hauser *et al.*, 2010).

These isoforms differ in amino acid sequence at positions 112 and 158, Apo E3 contains cysteine at 112 and arginine at 158, Apo E2 has cysteine at both positions, and E4 has arginine at both sites (Demet *et al.*, 2010).

While there are rare variants, among the variants of this gene, alleles E2, E3, and E4 constitute the common polymorphism found in most populations in relation to cardiovascular disease (Demet *et al.*, 2010).

Individuals with different apoE genotypes have different susceptibilities to CAD and studies have shown that the apo E4 allele is a genetic marker for CAD and an independent risk factor that predicts the incidence of cardiovascular disease (Li *et al.*, 2010).

The present study was carried out to determine the relation of ApoE gene polymorphisms and lipid profile in CAD defined by coronary angiography and assesses the findings in relation to the severity of disease in Egyptian patients. The current study showed significant higher age, male gender, smoking, hypertension and diabetes in CAD patients as compared with control.

These results agree with Peixoto *et al.*, (2007); Dias *et al.*, (2009) and Fallah *et al.*, (2011) who reported a predominance of male gender and mean

age in CAD patients. Bhanushali and Das, (2010) showed a significant difference in smoking and hypertension between CAD patients and control.

Grammer *et al.*, (2011) reported that patients with CAD were significantly older than controls. Current or past smoking, diabetes mellitus, and hypertension were more prevalent in CAD compared to controls. The current study showed significant higher total cholesterol (TC), triglycerides (TG), LDLc while lower HDLc in CAD patients as compared with control.

These results agree with those reported by Kharrazi *et al.*, (2006) and Bahri *et al.*, (2008) and explained this dyslipidemia as a classic risk factor for CAD.

The present study showed that the distribution of ApoE genotypes in CAD patients are as follow: E3E3, E2E3, E3E4, E4E4, E2E4 and E2E2 are 8.0%, 68%, 20%, 0.0%, 0.0% and 4.0% while in control are 20.0%, 60.0%, 20.0%, 0.0%, 0.0% and 0.0%. The frequency of E2, E3 and E4 alleles in CAD patients are as follow: 38.0%, 52.0% and 10.0% while in controls are 30.0%, 60.0% and 10.0% respectively.

The current study showed that E3E4 genotype is significantly higher in CAD patients as compared with controls while there was no significant difference as regards other genotypes. The study also showed that E2E3 genotype increased risk of CAD (p-value 0.955). These results are in agreement with Kharrazi *et al.*, (2006) and Singh *et al.*, (2008).

REFERENCES

- Bahri R; Esther E; Pedro M; Mohsen H; Khaldoun BH and Hassen C (2008): Apolipoprotein gene polymorphisms and plasma levels in healthy Tunisians and patients with coronary artery disease. *Lipids in Health and Disease*. 7(46): 1-9.
- Bhanushali A A and Das BR (2010): Genetic variants at the APOE, lipoprotein lipase (LpL), cholesteryl ester transfer protein (CETP), and endothelial nitric oxide (eNOS) genes and coronary artery disease (CAD): CETP Taq1 B2B2 associates with lower risk of CAD in Asian Indians. *J Community Genet*. 1 (2): 55-62.
- Chaaba R; Attia N; Hammami S; Smaoui M; Hamda KB; Mahjoub S and Hammami M (2008): Association between apolipoprotein E polymorphism, lipids, and coronary artery disease in Tunisian type 2 diabetes. *Journal of Clinical Lipidology*. 2: 360-364.
- Corwin E (2008): *Handbook of Pathophysiology*. 3rd Ed. Baltimore: Lippincott Williams & Wilkins.
- Demet AI; Ayşenur A; Mehmet K; Murat Y and Erdal D (2010): Relationship between severity of coronary artery disease and apolipoprotein E gene polymorphism. *Anadolu Kardiyol Derg*. 10: 202-208.
- Dias AMDC; Amália F; Claudia G; Maria D; Rafaela F; Rosemary N; Mariana F; Georgina S and Carlos A (2009): Severity of Angiographic Coronary Obstruction and the Apolipoprotein E Polymorphism in Acute Coronary Syndromes. *Arq Bras Cardiol*. 93(2): 206-215.
- Ding k and Kullo IJ (2009): Evolutionary Genetics of Coronary Heart Disease. *Circulation*. 119: 459-467.
- Entrez Gene (2009): Genes and mapped phenotypes. Apolipoprotein E. Gene ID 348.
- Fallah S; Morteza S; Mohsen F; Ladan HG; Ali S and Bahram S (2011): Effect of Apolipoprotein E genotypes on incidence and development of coronary stenosis in Iranian patients with coronary artery disease. *Journal of Clinical Laboratory Analysis*. 25 (1): 43-46.
- Grammer TB; Michael MH; Wilfried R; Marcus EK; Bernhard RW; Bernhard OB and Winfried MM (2011): Apolipoprotein E genotypes, circulating C-reactive protein and angiographic coronary artery disease (The Ludwigshafen Risk and Cardiovascular Health Study). *Atherosclerosis*. S0021-9150 (11) 00065-7.
- Graner M; Juhani K; Marjut V; Riitta MS; Kristiina N; Matti J; Markku SN; Mikko S and Marja-Riitta T (2008): Apolipoprotein E polymorphism is associated with both carotid and coronary atherosclerosis in patients with coronary

- artery disease. Nutrition, Metabolism and Cardiovascular diseases. 18 (4): 271-277.
- Hauser PS; Vasanthy N and Robert OR (2010): Apolipoprotein E: From lipid transport to neurobiology. Progress in Lipid Research. 742: xxx-xxx.
- Hoek KS, Schlegel NC, Eichhoff OM, Widmer DS, Praetorius C, Einarsson SO, *et al* (2008): Novel MITF targets identified using a two-step DNA microarray strategy. Pigment Cell & Melanoma Research; 21 (6): 665–76.
- Kharrazi HA; Vaisi R; Sabokroh AR and Pourmotabbed T (2006): Association between apolipoprotein E polymorphism and coronary artery disease in the Kermanshah population in Iran. Clinical Biochemistry. 39: 613–616.
- Li SS; Jie Y; Lan SL and Hai CW (2010): Apolipoprotein E Polymorphism and the Characteristics of Diseased Vessels in Male Chinese Patients With Angiographic Coronary Artery Disease: A Case-Case Study. Clin. Cardiol. 33 (6): E30–E34.
- Mazur M, Kuniewicz M, Klimek-Piotrowska W, Kucharska A, Mizia E, Mróz I, Wandzel-Loch B (2015): Human coronary sinus - from Galen to modern times. Folia Med Cracov, 55(1):5-15.
- National Heart, Lung and Blood Institute (NHLBI) (2009): National Heart Lung and Blood Institute. Diseases and Conditions Index. Heart and Vascular Diseases. Coronary artery disease.
- Peixoto DS; Tanajura LFL; Sousa AGRM; Centemero MP; Chaves AJ and Maia JP (2007): Pacientes com angina instável tratados por meio de intervenção escoro-narianas percutâneas no Novo Milênio: o que o caracteriza? Arq Bras Cardiol. 88 (1): 26-30.
- Singh PP; Singh M; Bhatnagar DP; Kaur TP and Gaur SK (2008): Apolipoprotein E polymorphism and its relation to plasma lipids in coronary heart disease. Indian J. Medical Sciences. 62 (3): 105- 112.
- Tascilar N; Dursun A; Ankarali H; Mungan V; Sumbuloglu S and Cabuk F (2009): Relationship of apoE polymorphism with lipoprotein (a), apoA, apoB and lipid levels in atherosclerotic infarct. Journal of the neurological sciences. 277: 17-21.

ARABIC SUMMERY

تحديد الأتماط الجينية للبروتين حامل الدهون (هـ) بواسطة التفاعل المتسلسل بالبوليميريز وعلاقته بدهنيات الدم في مرضى الشريان التاجي

سعيد السيد إبراهيم حسن¹ ، نجلاء خلوصي¹ ، رندا محمد طلعت²

1- قسم الوراثة الجزيئية المناعية - المركز القومي للبحوث .

2- قسم المشخصات الجزيئية - معهد بحوث الهندسة الوراثية والتكنولوجيا الحيوية - جامعة المنوفية

تعتبر أمراض الشرايين التاجية هي الأكثر شيوعاً في أمراض القلب ، وهي السبب في 35% من الوفيات في الولايات المتحدة الأمريكية حسب إحصائيات جمعية القلب الأمريكية وهي تنتج عن تراكم الجلطات في جدار الشريان التاجي الذي يمد عضلة القلب بالأوكسجين والتغذية . الأبوليبوبروتين (هـ) هو بروتين موجود في حاملات الدهون والدهون منخفضة الكثافة وهو يتحد مع مستقبلات على خلايا الكبد والخلايا الأخرى وهو ضروري لتكسير الليبوبروتين الغنية بالدهون الثلاثية .

قد أجريت هذه الدراسة على 35 من المرضى وقد تم تقسيمهم إلى مجموعتين :-

المجموعة الأولى : وتشمل 25 من مرضى تصلب الشريان التاجي وتتراوح أعمارهم بين 43-71 عام .

المجموعة الثانية : وتشمل 10 من الأصحاء تتراوح أعمارهم بين 29-54 عام .

كل المرضى تم إختيارهم من قسم القلب وحدة الرعاية المركزية بمستشفى القاهرة التخصصي وقد تم قياس التالي لكلاً من المرضى والمجموعة الضابطة .

- 1- أخذ التاريخ المرضي بالكامل .
 - 2- إجراء الفحص الإكلينيكي الشامل .
 - 3- رسم الشريان التاجي لمرضى القلب (القسطرة التاجية) .
 - 4- الفحوصات المعملية .
- تحديد تعدد أشكال الأبوليبوبروتين (هـ) جين باستخدام تفاعل البوليميراز التسلسلي وإنزيمات التحديد .
 - قياس نسبة الكوليسترول في الدم .
 - قياس نسبة الترايغليسرأيد في الدم .
 - قياس نسبة الدهون منخفضة الكثافة في الدم .
 - قياس نسبة الدهون عالية الكثافة في الدم .
 - قياس نسبة إنزيمات القلب والتروبونين .